Correction to “Triptonide Inhibits the Cervical Cancer Cell Growth via Downregulating the RTKs and Inactivating the Akt-mTOR Pathway”
First published: 21 June 2025
L.-n. Zhou, S.-q. Peng, X.-L. Chen, et.al., “Triptonide Inhibits the Cervical Cancer Cell Growth via Downregulating the RTKs and Inactivating the Akt-mTOR Pathway,” Oxidative Medicine and Cellular Longevity 2022, no. 1 (2022): 1–20, https://doi.org/10.1155/2022/8550817.
In the Results section, Figure 4a is incorrect. Specifically, the HeLa Ctr 0 h panel and TN (50 nM) 0 h panel were found to be the same image, caused by an error in the preparation of the manuscript. The correct image is shown below.
Figure 4
Triptonide inhibits human cervical cancer cell migration and invasion in vitro. Human cervical cancer cells (HeLa and SiHa) were treated with designated concentrations (10–50 nM) of Triptonide (“TN”); cell migration/invasion was evaluated by (a–d) “starch wound-healing assay”, (e) Transwell migration, and (f) Matrigel Transwell invasion assays. Data were presented as mean ± SD. For each assay, at least five independent experiments were repeated. “Ctr” stands for the vehicle control (0.1% DMSO). ∗p < 0.05 vs. “Ctr”.
We apologize for this error.
